Pharmacogenetics; is for exploring the different responses of people on the ground of variations of their genetic structures against treatment and medicine. Because of diversity of genetic structures which are important to function of the mechanism, people are differently affected by medicine for the better or for the worse. Nowadays thanks to some tests, the side effects or the efficacy of the medicine can be defined beforehand.
In our medical center for certain medicine pharmacogenetic analysis are realized. In this way before used, the toxicity of the medicine can be defined primarily. This method will save patients from side effects and will provide using alternative medicine.
Molecular Genetics
- EGFR DNA analysis (exon 18-21) - Lung cancer (Gefitinib/Iressa & Erlotinib/Tarceva)
- K-ras DNA analysis (exon 1-3) (codon 12&13, codon 61 and codon 146)
- PDGFRA DNA analysis - GIST (Imatinib/Gleevec)(drug dose-response)
- KIT DNA analysis - GIST (Imatinib/Gleevec)
- PDGFRB DNA analysis - Chronic leukemia and myeloproliferative disorders (with eosinophilia)
- ABL1 DNA analysis (exon 4-10) - Leukemia (Imatinib/Gleevec)
- DPYD DNA analysis (IVS14+1G>A) - 5-Fluorouracil toxicity
- JAK2 mutation analysis (V617F) - Myeloproliferative disorders
- FLT3 mutation analysis (D835) - Acute myeloid leukemia
- VKORC1 DNA analysis - Warfarin (Coumadin) toxicity
- VKORC1 S DNA analysis (1173C>T) - Warfarin (Coumadin) toxicity
- CYP2C9*2 DNA analysis (430C>T) - Warfarin (Coumadin) toxicity
- CYP2C9*3 DNA analysis (1075A>C) - Warfarin (Coumadin) toxicity
- CYP3A5*2 DNA analysis (27289C>A) - Xenobitica, toxins and steroid (endogenous substrates)
- CYP2C19*2 DNA analysis - Cardiovascular disease (Clopidogrel/Plavix resistance)
Molecular Cytogenetics (FISH)
- Her2/Neu (c-erbB2) FISH analysis - overexpression - Breast cancer (Trastuzumab/Herceptine)
- EGFR (Her1/erbB1) FISH analysis - overexpression - Lung cancer (Gefitinib/Iressa & Erlotinib/Tarceva)
